Sign in
AZRX Stock Price, Chart, Stats & News
AzurRx BioPharma, Inc.
Save
3.43M
Market cap
–
Current P/E
–
Forward P/E
AZRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 38.57% |
ROA | 20.81% |
ROE | 902.14% |
D/E | 0.03x |
Interest coverage ratio | -0.43x |
AZRX valuation
P/E | – |
P/S | – |
P/B | 0.20x |
P/CF | 1.01x |
P/FCF | 0.60x |
P/OCF | 1.01x |
PEG | -0.01x |
EV multiple | -0.75x |
About
AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101. MS1819 is an acid-stable lipase enzyme (LIP2), originating from Yarrowia lipolytica, which AzurRx is genetically engineering to address exocrine pancreatic insufficiency (EPI).
Similar securities
Based on sector and market capitalization
Report issue